Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about TASE:KDST
Recent news which mentions TASE:KDST
Kadimastem Takes Another Step Towards Signing the Merger Agreement with Nasdaq Listed IMCC
February 28, 2024
Tags
TASE:KDST
From
News Direct
Kadimastem advances towards Nasdaq: Company Signs a Memorandum of Understanding to Merge with a Company traded on the Nasdaq
February 16, 2024
Tags
TASE:KDST
From
News Direct
Kadimastem Receives Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes in India
February 07, 2024
Tags
TASE:KDST
From
News Direct
A peer reviewed article on Kadimastem's AstroRx® Cryopreserved off the Shelf Cell Product for the Treatment of ALS was Published in the Journal of Clinical Toxicology
January 25, 2024
Tags
TASE:KDST
From
News Direct
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA
January 22, 2024
Tags
TASE:KDST
From
News Direct
Kadimastem and iTolerance Submit Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting Request with FDA for Potential Cure for Type 1 Diabetes
November 07, 2023
Tags
TASE:KDST
From
News Direct
Kadimastem Receives US Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes
June 20, 2023
Tags
TASE:KDST
From
News Direct
Kadimastem Granted European Patent for Its Cell Selection and Enrichment Technology Used to Develop Its IsletRx Treatment for Diabetes
May 15, 2023
Tags
TASE:KDST
From
News Direct
Kadimastem and iTolerance Sign Agreement and Receive US$1 Million from BIRD Foundation
May 09, 2023
Tags
TASE:KDST
From
News Direct
Kadimastem Earns FDA Approval of its IND Application For its US Multi-Site Phase IIa Clinical Trial of AstroRx® to Treat ALS
March 20, 2023
Tags
TASE:KDST
From
News Direct
Kadimastem Submits IND Application to the FDA for its Phase IIa Clinical Trial with AstroRx® for the Treatment of ALS
February 20, 2023
Tags
TASE:KDST
From
News Direct
Kadimastem's Clinical Trial in ALS Patients was Publicized in the Journal of Translational Medicine
February 15, 2023
Tags
TASE:KDST
From
News Direct
Kadimastem Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening
February 06, 2023
Tags
TASE:KDST
From
News Direct
Kadimastem Receives US Patent For Amyotrophic Lateral Sclerosis (ALS) Treatment
August 09, 2022
Tickers
ALS
Tags
TASE:KDST
From
News Direct
Kadimastem and Implant Therapeutics, Inc. Sign an Evaluation Agreement Towards the Potential Licensing of “Immune Evasive” Cells
June 08, 2022
Tags
TASE:KDST
From
News Direct
Kadimastem Awarded Patent in Japan for AstroRx® For ALS and Drug Screening
May 30, 2022
Tags
TASE:KDST
From
News Direct
Kadimastem Expands R&D Program to Include Multiple Sclerosis
May 18, 2022
Tags
TASE:KDST
From
News Direct
Kadimastem Receives Grant for a Total Budget of NIS 10 Million ($3.1 million) from the Israeli Innovation Authority
March 03, 2022
Tags
TASE:KDST
From
News Direct
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority
December 13, 2021
Tags
TASE:KDST
From
News Direct
Kadimastem Raises $5 million In Private Placement
October 26, 2021
Tags
TASE:KDST
From
News Direct
Kadimastem Raises NIS 16.1 million ($5 million) In Private Placement
October 25, 2021
Tags
TASE:KDST
From
News Direct
Kadimastem Holds Successful Preliminary Meeting with the FDA (INTERACT) Regarding IsletRx for the Treatment of Diabetes
October 12, 2021
Tags
TASE:KDST
From
News Direct
Kadimastem Patent for cell selection of beta cells to Treat and Potentially Cure Diabetes was Granted in Japan
July 21, 2021
Tags
TASE:KDST
From
News Direct
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.